<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711099</url>
  </required_header>
  <id_info>
    <org_study_id>ANGEL_v01</org_study_id>
    <nct_id>NCT01711099</nct_id>
  </id_info>
  <brief_title>Efficacy of Extracorporeal Shockwave Myocardial Revascularization</brief_title>
  <acronym>ANGEL</acronym>
  <official_title>Hungarian Study on the Efficacy of Extracorporeal Shockwave Myocardial Revascularization in Patients With Therapy-refracter Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salus Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salus Ltd.</source>
  <brief_summary>
    <textblock>
      Clinical research to justify effectiveness of the Extracorporeal Shockwave Myocardial&#xD;
      Revascularization (ESMR) Therapy for treatment of patients with reversible myocardial&#xD;
      ischemia secondary to Coronary Artery Disease (CAD) and therapy resistant stable angina&#xD;
      pectoris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in myocardial ischaemia profile during dobutamine induced stress echocardiography</measure>
    <time_frame>baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the angina pectoris CCS Stage</measure>
    <time_frame>baseline and 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in angina status using Seattle Angina Questionnaire</measure>
    <time_frame>baseline and 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in walking time using the modified Bruce exercise test</measure>
    <time_frame>baseline and 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in basal transthoracal echocardiographic parameters</measure>
    <time_frame>baseline and 3, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrease in nitrate use during the unchanged everyday activity reported by the patients in the &quot;Nitrate Usage Log&quot;</measure>
    <time_frame>baseline and 3, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Refractory Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>ESMR treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy</intervention_name>
    <arm_group_label>ESMR treated</arm_group_label>
    <other_name>Cardiospec system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a signed Informed Consent Form.&#xD;
&#xD;
          -  Patient's current and past medical condition and status be assessed using previous&#xD;
             medical history, complete physical examination and the physicians (principle&#xD;
             investigator's) medical opinion.&#xD;
&#xD;
          -  Patient is diagnosed with chronic angina pectoris for at least 6 weeks. Diagnosis is&#xD;
             based on medical history, complete physical examination, and core labs.&#xD;
&#xD;
          -  Patients who no longer receive benefit from additional revascularization procedures&#xD;
             (i.e. CABG or Angioplasty). Certification will be made by Heart Team.&#xD;
&#xD;
          -  Patient demonstrates Exercise Tolerance Time (ETT) duration &lt; 10 minutes on Modified&#xD;
             Bruce protocol.&#xD;
&#xD;
          -  Patient had at least one documented myocardial segment with reversible ischemia.&#xD;
&#xD;
          -  Patient is under optimum medical therapy for angina for at least 6 weeks. The optimal&#xD;
             treatment plan is tailored to a person's age, the presence of other medical&#xD;
             conditions, lifestyle, medication side effects, etc. Medical therapies for stable&#xD;
             angina include ACE-inhibitors, Nitrates, Beta Blockers and Calcium Channel Blockers,&#xD;
             trimetazidine, ivabradin. Combination of any of 3 above mentioned drugs will be&#xD;
             considered as optimum medical therapy.&#xD;
&#xD;
          -  Patient has an echocardiographic acoustic window to the target area in the myocardium&#xD;
             utilizing one of the following views: apical 2 chamber view (2CH), apical 4 chamber&#xD;
             view (4CH), modified parasternal long axis view (LAX) and parasternal short axis view&#xD;
             (SAX).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who will substantially benefit from additional revascularization procedures&#xD;
             such as additional CABG or angioplasty therapies. This determination will be made and&#xD;
             certified by the Heart Team.&#xD;
&#xD;
          -  Patient has active endocarditis, myocarditis or pericarditis.&#xD;
&#xD;
          -  Patient with moderately severe or severe valvular disease.&#xD;
&#xD;
          -  Patient with known intraventricular thrombus.&#xD;
&#xD;
          -  Patients who have active or non-active implantables, such as pacemakers,&#xD;
             defibrillators, abandoned leads, or electrodes.&#xD;
&#xD;
          -  Patient for who shock waves applied over any implanted device that releases substances&#xD;
             or medications to the periphery (such as insulin pumps).&#xD;
&#xD;
          -  Patient is pregnant.&#xD;
&#xD;
          -  Patient with severe chronic lung disease (emphysema, pulmonary fibrosis) with&#xD;
             difficult access to ultrasonic acoustic window.&#xD;
&#xD;
          -  Patients for who shock waves applied over the area of healing fracture.&#xD;
&#xD;
          -  Patients for who shock waves applied over the area of bone growth.&#xD;
&#xD;
          -  Patients for who shock waves applied to the area of malignancy.&#xD;
&#xD;
          -  Prior invasive malignancy, except non-melanomatous skin cancer or other malignancies&#xD;
             with a documented disease-free survival for a minimum of 5 years.&#xD;
&#xD;
          -  By the physician decision there is underlying concomitant disease or circumstance what&#xD;
             may negatively influence the management of the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Béla Merkely, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University Heart Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Béla Merkely, Prof.</last_name>
    <phone>+36 1 4586840</phone>
    <email>titkarsag@kardio.sote.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kelen Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imre Lukács, MD</last_name>
      <phone>+36 20 914 7300</phone>
      <email>luxi6@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Imre Lukács, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béla Merkely, Prof</last_name>
      <phone>+36 1 4586840</phone>
      <email>titkarsag@kardio.sote.hu</email>
    </contact>
    <investigator>
      <last_name>Zoltán Jambrik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

